FRX:CC News and Press, Fennec Pharmaceuticals Inc.

~ University of Arizona Cancer Center Initiating Study to Explore Use of PEDMARK ® in AYA & Adult Patients with Solid Tumors Receiving Cisplatin ~ ~ This New Study and Other Independent, Institution-Led Research Continues to Expand Real-World Validation of PEDMARK ® ...

RESEARCH TRIANGLE PARK, N.C., March 31, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on March 17, 2026, the Compensation Committee of the Companyȁ...

2026-03-24 12:24:48 ET Fennec Pharmaceuticals Inc. (FENC) Q4 2025 Earnings Call March 24, 2026 8:30 AM EDT... Read the full article on Seeking Alpha For further details see: Fennec Pharmaceuticals Inc. (FENC) Q4 2025 Earnings Call Transcript

2026-03-24 07:29:57 ET More on Fennec Pharmaceuticals Seeking Alpha’s Quant Rating on Fennec Pharmaceuticals Historical earnings data for Fennec Pharmaceuticals Financial information for Fennec Pharmaceuticals Read the full article on Seeking Alpha ...

~ Delivered Record Annual Revenue with Full-Year Net PEDMARK ®  Product Sales of $44.6 Million, Representing 50% Year-Over-Year Growth, and Q4 2025 Net Product Sales of $13.8 Million, Representing 75% Growth Over Q4 2024 Net Product Sales ~ ~ Executed on 2025 Clinical Data Stra...

2026-03-20 23:02:42 ET Fennec Pharmaceuticals Inc. ( TSE:FRX – Get Free Report ) crossed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of C$10.80 and traded as low as C$10.18. Fennec Pharmaceuticals shares last traded at C...

RESEARCH TRIANGLE PARK, N.C., March 18, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its full year and fourth quarter 2025 financial results before the opening of t...

RESEARCH TRIANGLE PARK, N.C., March 16, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announces that it has entered into an agreement with Cipla Limited and Cipla USA, Inc. to settle the litigation between them regarding Ci...

Fennec Pharmaceuticals Inc. (FRX:CA) is expected to report $0.04 for Q4 2025 NervGen Pharma Corp. (NGEN:CA) is expected to report $-0.09 for Q4 2025 High Tide Inc. (HITI:CA) is expected to report $0.01 for Q1 2026 Encore Energy Corp. (EU:CA) is expected to report $-0.09 for Q4 2025 ...

Akita Drilling Ltd. Class A Non-Voting Shares (AKT.A:CA) is expected to report $0.02 for Q4 2025 Constellation Software Inc. (CSU:CA) is expected to report $40.88 for Q4 2025 Rubellite Energy Corp. (RBY:CA) is expected to report $0 for Q4 2025 Fennec Pharmaceuticals Inc. (FRX:CA) is e...